Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.

Leukemia & lymphoma - 1 Jul 2025

Gruessner Christine, Wiestner Adrian, Sun Clare

Abstract excerpt

Bruton tyrosine kinase (BTK), an essential component of the B-cell receptor (BCR) signaling pathway, is a validated target in chronic lymphocytic leukemia. Ibrutinib, acalabrutinib, and zanubrutinib are covalent BTK inhibitors (cBTKi) that bind to residue C481, leading to sustained target inhibition. A significant proportion of patients develop resistance to continuous cBTKi therapy, predominantly via mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Molecular Targeted Therapy

Share to Piperidines

Share to Protein Kinase Inhibitors

Share to Receptors, Antigen, B-Cell

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 39972943
DOI: 10.1080/10428194.2025.2466101
PMCID: PMC12221821

Genes

BTK
BCR
PLCG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.PMID 39972943Read ↗

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted TherapySemantic proximity Read ↗

BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitorsSemantic proximity Read ↗

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.Semantic proximity Read ↗

When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).Semantic proximity Read ↗

BTK inhibitors in CLL: second-generation drugs and beyond.Semantic proximity Read ↗

Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?Semantic proximity Read ↗

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.Semantic proximity Read ↗

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future DirectionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.